U-M Pharmacy Dean James Dalton Inducted Into National Academy of Medicine
Dean Dalton is widely recognized for his research on selective androgen receptor modulators (SARMs). In 1997, Dean Dalton’s group was the first to report on SARMs, a discovery that launched a new class of potential drugs to treat age and disease-related muscle loss.
Prior to joining U-M, Dean Dalton was an assistant/associate professor at the University of Tennessee (1992-2000) and professor and chair in the Division of Pharmaceutics at Ohio State (2000-2007). He left on an entrepreneurial leave of absence from Ohio State in 2005 to join the small, Memphis-based drug development company GTx Inc. as vice president of preclinical research and development and chief scientific officer to advance the clinical development of SARMs. He stayed at GTx through 2014, then joined U-M as professor and dean of the College of Pharmacy.
Dean Dalton has received many awards and honors during his career, mentoring over 20 PhD students in his UT and Ohio State labs, and twice winning the Excellence in Teaching Award. He’s co-authored over 300 abstracts and is an inventor on over 400 patent applications related to SARMs, selective estrogen receptor alpha and beta ligands, tubulin antagonists, and receptor tyrosine kinase inhibitors. He is a fellow in the American Association for the Advancement of Science and the American Association of Pharmaceutical Scientists.
Dean Dalton earned a Bachelor of Science in pharmacy from the University of Cincinnati and a PhD in pharmaceutics and pharmaceutical chemistry from Ohio State. He was a staff pharmacist at Kettering Medical Center in Kettering, Ohio, and had a postdoctoral fellowship in the Division of Pharmaceutics and Pharmaceutical Chemistry at Ohio State.